A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels

Journal of Clinical Psychopharmacology

Volumn 28, Issue 1, 2008, Pages 21-26

  Roerig, James L ^a,b,d   Steffen, Kristine J ^b,c   Mitchell, James E ^a,b   Crosby, Ross D ^a,b   Gosnell, Blake A ^a,b  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b NEUROPSYCHIATRIC RESEARCH INSTITUTE   (United States)

^c NORTH DAKOTA STATE UNIVERSITY   (United States)

^d UND School of Medicine & Health Sciences Southeast Campus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; GHRELIN; HALOPERIDOL; MOLINDONE; OLANZAPINE; PLACEBO; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

ADULT; APPETITE; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EXPOSURE; DRUG TOLERABILITY; EATING; FEEDING BEHAVIOR; FEMALE; GHRELIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEEDING BEHAVIOR; FEMALE; GHRELIN; HUMANS; MALE; RISPERIDONE; WEIGHT GAIN;

EID: 38349168105     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e3181613325     Document Type: Article

References (31)

1. Casey DE. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr. 2006;11(7 suppl 7):25-31.
2. Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006;86:234-243.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
4. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
5. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf. 2006;29:303-319.
6. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101:277-288.
7. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
8. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol. 2003;28:519-526.
9. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20:368-378.
10. Theisen FM, Haberhausen M, Firnges MA, et al. No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007;7:275-281.
11. Kim SF, Huang AS, Snowman AM, et al. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci. 2007;104:3456-3459.
12. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth hormone releasing acylated peptide from stomach. Nature. 1999;402:656-660.
13. Bowers CY. A natural growth hormone releasing peptide begets natural ghrelin. J Endocrinol Metab. 2001;86:1464-1469.
14. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000;141:4325-4328.
15. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2001;407:908-913.
16. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409:194-198.
17. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120:337-345.
18. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin an endogenous G H secretagogue is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;50:227-232.
19. Cummings DE, Purnell JQ, Frayo RS, et al. A pre-prandial rise in plasma ghrelin level suggests a role in meal initiation in humans. Diabetes. 2001;50:1714-1719.
20. Tschöp M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest. 2001;24:RC19-RC21.
21. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992-5995.
22. Hosojima H, Togo T, Odawara T, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol. 2006;20:75-79.
23. Himmerich H, Fulda S, Kunzel HE, et al. Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology. 2005;52:11-16.
24. Palik E, Birkas KD, Faludi G, et al. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract. 2005;68(suppl 1):S60-S64.
25. Murashita M, Kusumi I, Inoue T, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology. 2005;30:106-110.
26. Sporn AL, Bobb AJ, Gogtay N, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry. 2005;44:925-933.
27. Theisen FM, Gebhardt S, Bromel T, et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm. 2005;112:1411-1416.
28. Togo T, Hasegawa K, Miura S, et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl). 2004;172:230-232.
29. Roerig JL, Mitchell JE, de Zwaan M, et al. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J Clin Psychopharmacol. 2005;25:413-418.
30. Tschop M, Séller C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707-709.
31. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature. 2006;444:854-859.